ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

[News]

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.

More... (http://www.news-medical.net/news/20150602/ASCO-2015-Berg-presents-data-from-BPM-31510-Phase-Ib-trial-for-solid-tumors.aspx)